ADHD

Alcobra Ltd (ADHD) Stock Pummeled on Failed ADHD Drug Trial

By William White, InvestorPlace Writer
Alcobra Ltd (ADHD) stock was hit hard on Tuesday following a failed Phase 3 drug trial for its ADHD drug Metadoxine Extended Release.

3 Pharmaceutical Stocks to Sell Now

By Portfolio Grader
For the current week, the overall ratings of three pharmaceutical stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

5 Pharmaceutical Stocks to Sell Now

By Portfolio Grader
This week, the ratings of five pharmaceutical stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

3 Pharmaceutical Stocks to Sell Now

By Portfolio Grader
This week, the overall grades of three pharmaceutical stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

3 Pharmaceutical Stocks to Sell Now

By Portfolio Grader
The ratings of three pharmaceutical stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

5 Pharmaceutical Stocks to Sell Now

By Portfolio Grader
This week, the overall grades of five pharmaceutical stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

3 Pharmaceutical Stocks to Sell Now

By Portfolio Grader
This week, the ratings of three pharmaceutical stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").